Abivax SA

ABVX · NYSE

$88.01−$2.22 (−2.46%)TodayMarket closed · Oct 23, 7:56 PM ET

Prev close $90.23

ABVX analyst rating

BuyConsensus of 13 analysts over the last 12 months. 92% rate it a buy.

Strong buy0
Buy12
Hold1
Underperform0
Sell0

12-month price target · 11 analysts

Average $168.07 (+91.0% upside)

Low: $78.36
Now: $88.01
High: $209.48

Upgrades and downgrades

The latest rating actions, newest first

ABVX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Oct 21, 2026	Maintains	Neutral	$118.00 → $96.00	48%
Guggenheim	Oct 20, 2026	Maintains	Buy	$175.00	49%
Truist Securities	Sep 22, 2026	Maintains	Buy	$155.00 → $151.00	48%
Wedbush	Sep 22, 2026	Maintains	Neutral	$140.00 → $118.00	48%
Barclays	Sep 22, 2026	Maintains	Overweight	$148.00	49%
Goldman Sachs	Sep 10, 2026	Initiates	Buy	$155.00	20%
BTIG	Sep 5, 2026	Maintains	Buy	$175.00	35%
Piper Sandler	Jul 9, 2026	Maintains	Overweight	$165.00 → $175.00	55%
Truist Securities	Jul 2, 2026	Maintains	Buy	$135.00 → $155.00	48%
Citizens	Jul 1, 2026	Maintains	Market Outperform	$187.00	41%

The case for and against

Updated Oct 21, 2026

Bull case

Abivax is viewed favorably because obefazimod addresses a large unmet need in ulcerative colitis, where no active, safe, easy-to-prescribe oral option has clearly succeeded and Phase 3 data show durable efficacy versus advanced therapies with simpler QD oral dosing. Its safety profile has also improved materially, with non-melanoma skin cancer rates remaining within expected UC background ranges and no clear drug-specific signal, removing an important overhang for adoption. Fundamentally, the opportunity is amplified by a growing IBD market, management’s 2025 to 2032 UC market growth outlook, and stronger-than-expected maintenance data that support a potentially best-in-class backbone for both 1L use and combination regimens.

Bear case

Abivax is burdened by a highly concentrated, single-asset profile in obefazimod, with valuation tied to uncertain Phase 3 outcomes in ulcerative colitis and Crohn’s disease and a DCF anchored to 2027E net income that remains highly speculative. The negative outlook reflects elevated clinical and regulatory risk, the possibility of safety signals halting development, and the need to raise capital under less favorable assumptions, which could dilute shareholders and pressure returns. Even where management disputes related adverse events, the company still faces commercial execution risk, competition from current and future therapies, and manufacturing or shipment challenges that could limit eventual sales.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.